HIGHLIGHTS
- who: Geeta Geeta Sharma et al. from the Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy have published the Article: Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes, in the Journal: Cancers 2018, 10, 62 of /2018/
SUMMARY
Over the last decade, the development of drugs that selectively target driver oncogenes has played an important role to establish novel treatment guidelines in the field of oncology. ALK was first described in 1994 as the NPM-ALK fusion_protein that is expressed in the majority of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.